207 related articles for article (PubMed ID: 24462901)
1. Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors.
Wang J; Lu Z; Yeung BZ; Wientjes MG; Cole DJ; Au JL
J Control Release; 2014 Mar; 178():79-85. PubMed ID: 24462901
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors.
Wang J; Lu Z; Wang J; Cui M; Yeung BZ; Cole DJ; Wientjes MG; Au JL
J Control Release; 2015 Oct; 216():103-10. PubMed ID: 26272765
[TBL] [Abstract][Full Text] [Related]
3. Intravenous siRNA Silencing of Survivin Enhances Activity of Mitomycin C in Human Bladder RT4 Xenografts.
Cui M; Au JL; Wientjes MG; O'Donnell MA; Loughlin KR; Lu Z
J Urol; 2015 Jul; 194(1):230-7. PubMed ID: 25681288
[TBL] [Abstract][Full Text] [Related]
4. Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer.
Salzano G; Navarro G; Trivedi MS; De Rosa G; Torchilin VP
Mol Cancer Ther; 2015 Apr; 14(4):1075-84. PubMed ID: 25657335
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel tumor-priming enhances siRNA delivery and transfection in 3-dimensional tumor cultures.
Wong HL; Shen Z; Lu Z; Wientjes MG; Au JL
Mol Pharm; 2011 Jun; 8(3):833-40. PubMed ID: 21417439
[TBL] [Abstract][Full Text] [Related]
6. Activity of drug-loaded tumor-penetrating microparticles in peritoneal pancreatic tumors.
Lu Z; Tsai M; Wang J; Cole DJ; Wientjes MG; Au JL
Curr Cancer Drug Targets; 2014; 14(1):70-8. PubMed ID: 24200079
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal administration of a small interfering RNA targeting nuclear factor-kappa B with paclitaxel successfully prolongs the survival of xenograft model mice with peritoneal metastasis of gastric cancer.
Inoue M; Matsumoto S; Saito H; Tsujitani S; Ikeguchi M
Int J Cancer; 2008 Dec; 123(11):2696-701. PubMed ID: 18798274
[TBL] [Abstract][Full Text] [Related]
8. Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy.
Xu C; Liu W; Hu Y; Li W; Di W
Theranostics; 2020; 10(7):3325-3339. PubMed ID: 32194871
[TBL] [Abstract][Full Text] [Related]
9. Versatility of Particulate Carriers: Development of Pharmacodynamically Optimized Drug-Loaded Microparticles for Treatment of Peritoneal Cancer.
Au JL; Lu Z; Wientjes MG
AAPS J; 2015 Sep; 17(5):1065-79. PubMed ID: 26089090
[TBL] [Abstract][Full Text] [Related]
10. Growth inhibition and chemo-radiosensitization of head and neck squamous cell carcinoma (HNSCC) by survivin-siRNA lentivirus.
Khan Z; Khan AA; Prasad GB; Khan N; Tiwari RP; Bisen PS
Radiother Oncol; 2016 Feb; 118(2):359-68. PubMed ID: 26747757
[TBL] [Abstract][Full Text] [Related]
11. The antitumor effect of a thermosensitive polymeric hydrogel containing paclitaxel in a peritoneal carcinomatosis model.
Yu J; Lee HJ; Hur K; Kwak MK; Han TS; Kim WH; Song SC; Yanagihara K; Yang HK
Invest New Drugs; 2012 Feb; 30(1):1-7. PubMed ID: 20669041
[TBL] [Abstract][Full Text] [Related]
12. Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer.
Lu Z; Tsai M; Lu D; Wang J; Wientjes MG; Au JL
J Pharmacol Exp Ther; 2008 Dec; 327(3):673-82. PubMed ID: 18780831
[TBL] [Abstract][Full Text] [Related]
13. Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer.
Wu J; Wang Q; Dong X; Xu M; Yang J; Yi X; Chen B; Dong X; Wang Y; Lou X; Xia F; Wang S; Dai J
Theranostics; 2021; 11(8):3710-3724. PubMed ID: 33664857
[TBL] [Abstract][Full Text] [Related]
14. Tumor-penetrating codelivery of siRNA and paclitaxel with ultrasound-responsive nanobubbles hetero-assembled from polymeric micelles and liposomes.
Yin T; Wang P; Li J; Wang Y; Zheng B; Zheng R; Cheng D; Shuai X
Biomaterials; 2014 Jul; 35(22):5932-43. PubMed ID: 24746965
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of intraperitoneal chemotherapy with paclitaxel targeting peritoneal micrometastasis as revealed by GFP-tagged human gastric cancer cell lines in nude mice.
Ohashi N; Kodera Y; Nakanishi H; Yokoyama H; Fujiwara M; Koike M; Hibi K; Nakao A; Tatematsu M
Int J Oncol; 2005 Sep; 27(3):637-44. PubMed ID: 16077911
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
Wang S; Huang J; Lyu H; Cai B; Yang X; Li F; Tan J; Edgerton SM; Thor AD; Lee CK; Liu B
Breast Cancer Res; 2013; 15(5):R101. PubMed ID: 24168763
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis.
Chen X; Zhang Y; Tang C; Tian C; Sun Q; Su Z; Xue L; Yin Y; Ju C; Zhang C
Int J Pharm; 2017 Aug; 529(1-2):102-115. PubMed ID: 28642204
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel-loaded polymeric microparticles: quantitative relationships between in vitro drug release rate and in vivo pharmacodynamics.
Tsai M; Lu Z; Wientjes MG; Au JL
J Control Release; 2013 Dec; 172(3):737-44. PubMed ID: 24056144
[TBL] [Abstract][Full Text] [Related]
19. Anisamide-targeted PEGylated gold nanoparticles designed to target prostate cancer mediate: Enhanced systemic exposure of siRNA, tumour growth suppression and a synergistic therapeutic response in combination with paclitaxel in mice.
Luan X; Rahme K; Cong Z; Wang L; Zou Y; He Y; Yang H; Holmes JD; O'Driscoll CM; Guo J
Eur J Pharm Biopharm; 2019 Apr; 137():56-67. PubMed ID: 30779980
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
